Recombinant Human FGFR4 His-tag Protein, CF

In a Human FGF acidic/FGF1 antibody (AF232) coated plate, in the presence of 50.0 ng/mL of Recombinant Human FGF acidic/FGF1 (232-FA), Recombinant Human FGFR4 His-tag Protein (Catalog # 11120-FR) binds with an ED50 of 30.0‑180 ng/mL.

2 μg/lane of Recombinant Human FGFR4 His-tag Protein (Catalog # 11120-FR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-70 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human FGFR4 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. In a Human FGF acidic/FGF1 antibody (Catalog # AF232) coated plate, in the presence of 50.0 ng/mL of Recombinant Human FGF acidic/FGF1 (Catalog # 232-FA), Human FGFR4 His-tag Protein binds with an ED₅₀ of 30.0-180 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human FGFR4 protein
  Leu22-Asp369, with a C-terminal 6-His tag
• Accession #: P22455.2
• N-terminal Sequence: Leu22
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 39 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-70 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human FGFR4 His-tag Protein, CF

• CD334 antigen
• CD334
• EC 2.7.10
• EC 2.7.10.1
• FGF R4
• FGFR4
• FGFR-4
• fibroblast growth factor receptor 4
• JTK2hydroxyaryl-protein kinase
• MGC20292
• protein-tyrosine kinase
• TKF
• tyrosine kinase related to fibroblast growth factor receptor
• tyrosylprotein kinase

Background

Fibroblast growth factor receptor 4 (FGFR4) belongs to a family of type I transmembrane tyrosine kinases which mediate the biological functions of FGFs that are involved in a multitude of physiological and pathological cellular processes (1). The FGFR family is comprised of 4 structurally conserved members (FGFR1-4) all possessing and extracellular domain (ECD) with three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain (1, 2). The ECD of mature human FGFR4 shares 90% amino acid sequence identity with mouse FGFR4. Alternative splicing of the IgIII domain generates multiple forms of FGFR1-3, but FGFR4 does not have a splice variant (3, 4). FGFR4 exhibits distinct and varying binding affinities for different FGF ligands, with FGF1, FGF4, and FGF8 showing the highest affinity (4). FGFRs mediate the FGF signaling cascade which regulate developmental processes including cellular proliferation, differentiation, and migration, morphogenesis, and patterning (5). FGFRs transduce the signals through three dominant pathways including RAS/MAPK, PI3k/AKT, and PLC gamma (6). FGFR4 is expressed at high levels during embryonic development and is required for the maintenance of both lipid and glucose metabolism as well as an established role in cholesterol metabolism (7). Overexpression of the FGFR4 has been reported in several solid tumors including breast cancer, prostate cancer, pancreatic cancer, and renal cell carcinoma (4, 8). Further, FGFR4 expression is significantly upregulated in most liver cancer cases, and enhanced FGF19-FGFR4 signaling is linked to hepatocellular carcinoma progression, metastasis, and poor survival (8). FGFR4 is being explored as a potential therapeutic target for breast cancer and other solid tumors (9).

1. Ornitz, D.M. and Itoh, N. (2015) Wiley Interdiscip Rev Dev, Biol. 4:215.
2. Zhang, X. et al. (2006) J Biol Chem. 281:15694.
3. Ferguson, H.R. et al. (2021) Signaling. Cells 10:1201.
4. Lang, L. and Teng, Y. (2019) Cells. 8:31.
5. Xie, Y. et al. (2020) Sig Transduct Target Ther 5:181.
6. Mossahebi-Mohammadi, M. et al. (2020) Front Cell Dev Biol. 18:79.
7. Huang, X. et al. (2007) Diabetes 56:2501.
8. Liu, Y. et al. (2020) Front Cell Dev Biol. 8:95.
9. Levine, K.M. et al. (2020) Pharmacol Ther. 214:107590.

Bioinformatics

• Uniprot:
  • P22455.2()